Fox Chase Cancer Center's Daly Promoted to Senior Member
PHILADELPHIA (October 30, 2000) — Dr. Mary B. Daly, a medical oncologist and epidemiologist, has been promoted to senior member of the population science division of Fox Chase Cancer Center.
Daly joined Fox Chase Cancer Center in 1989 and initiated its Margaret Dyson Family Risk Assessment Program in 1991 to help women cope with an increased risk of breast or ovarian cancer. The program, which is still directed by Daly, was among the first of its kind in the nation and has become a model for risk-assessment programs in cancer centers around the country. In addition, Daly is a leading authority on ethical issues concerning family cancer registries and all aspects of genetic counseling.
Daly's work in breast cancer prevention is nationally recognized. She was principal investigator at Fox Chase for the first national Breast Cancer Prevention Trial, a clinical study designed to find out if the drug tamoxifen can prevent breast cancer in women at high risk for the disease. She is also principal investigator for a new breast-cancer prevention study, which began in May 1999. This trial, a Study of Tamoxifen and Raloxifene (STAR), will compare the effectiveness of two drugs.
Before joining Fox Chase, Daly was stationed at Wilford Hall Medical Center, Lackland Air Force Base, Texas, where she held the rank of lieutenant colonel. As chief of hematology and medical oncology there, Daly helped develop the first bone-marrow transplant program operated by the Department of Defense.
Daly is a member of the Board of Scientific Counselors at the National Cancer Institute and the president-elect of the American Society of Prevention Oncology. She is a fellow of the American College of Physicians and a member of the American College of Epidemiology, International Epidemiology Association, American Association of Cancer Education and several other professional organizations. In 1995 she was appointed to the Board of Scientific Advisors for the Division of Cancer Prevention and Control at the National Cancer Institute and the Board of Directors at the American Cancer Society, Philadelphia Division.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.